Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 28:18:5-7.
doi: 10.1016/j.jdin.2024.08.021. eCollection 2025 Feb.

Resistance to cosmetic botulinum toxin A: A 15-patient case series across 12 sites

Affiliations

Resistance to cosmetic botulinum toxin A: A 15-patient case series across 12 sites

Carlos G Wambier et al. JAAD Int. .
No abstract available

Keywords: botox; botulinum toxin A; botulinum toxin B; cosmetic dermatology; neuromodulator; neurotoxin; rhytids; wrinkles.

PubMed Disclaimer

Conflict of interest statement

Dr C. G. Wambier has served a consultant for Allergan Aesthetics, AbbVie Company and as a speaker of Galderma Laboratories and cosmetic dermatologic surgery editor of the Surgical & Cosmetic Dermatology Journal and Brazilian Society of Dermatology (SBD). Dr Bertucci has served as a speaker, consultant, and/or investigator for Allergan Aesthetics, AbbVie Company, Clarion Medical Technologies, Cutera, Evolus, Galderma, L’Oreal, Revance, and Teoxane. Dr Carruthers has served as consultant for Acorn, Alastin, Appiell, Allergan Aesthetics, AbbVie Company, Avari, Bonti (now with Allergan/AbbVie), Del Nova, Evolus, Fount Bio, In Mode, Inverse Genomic Ltd, Jeune Aesthetics, Merz, Revance Biopharma, Object Pharma, Sofwave, is an author and editor for Elsevier, is an author for “Up to Date” Neuromodulators and Fillers, is an assistant editor for Dermatologic Surgery, is a reviewer for the Aesthetic Surgery Journal, Ophthalmic Plastic and Reconstructive Surgery, and Plastic and Reconstructive Surgery. Dr Kaufman has been an investigator for Allergan Aesthetics, AbbVie Company, Croma, Galderma, MedyTox, Merz, and Revance. Dr Guadanhim is speaker and investigator for Allergan Aesthetics and AbbVie Company. Dr Hexsel is a consultant for Galderma Laboratories, and cosmetic dermatology editor of the Surgical & Cosmetic Dermatology Journal and Brazilian Society of Dermatology (SBD). Drs Mirza, S. P. F. Wambier, Martin, Sterling, Brasileiro, Marçon, Brown, and Rosenberg have no conflicts of interest to declare.

References

    1. Ho W.W.S., Albrecht P., Calderon P.E., et al. Emerging trends in botulinum neurotoxin A resistance: an international multidisciplinary review and consensus. Plast Reconstr Surg Glob Open. 2022;10(6) doi: 10.1097/GOX.0000000000004407. - DOI - PMC - PubMed
    1. Torres S., Hamilton M., Sanches E., Starovatova P., Gubanova E., Reshetnikova T. Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports. Clin Cosmet Investig Dermatol. 2014;7:11–17. doi: 10.2147/CCID.S51938. - DOI - PMC - PubMed
    1. Pirazzini M., Carle S., Barth H., Rossetto O., Montecucco C. Primary resistance of human patients to botulinum neurotoxins A and B. Ann Clin Transl Neurol. 2018;5(8):971–975. doi: 10.1002/acn3.586. - DOI - PMC - PubMed
    1. Lowe N.J., Yamauchi P.S., Lask G.P., Patnaik R., Moore D. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther. 2002;4(1):15–18. doi: 10.1080/14764170260030117. - DOI - PubMed
    1. Brin M.F., Lew M.F., Adler C.H., et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53(7):1431–1438. doi: 10.1212/wnl.53.7.1431. - DOI - PubMed

LinkOut - more resources